SCHEMBL12430601

SCHEMBL12430601

COc1cccc2c(Nc3cc(C4CC4)[nH]n3)nc(Sc3ccc(NC(C)=O)cc3)nc12

nearest known ligand 0.74

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
AURKB Q96GD4 10/20 0.74
SRC P12931 7/20 0.74
GSK3B P49841 7/20 0.74
AURKA O14965 9/20 0.55
AURKC Q9UQB9 1/20 0.55
IGF1R P08069 5/20 0.45
PLK4 O00444 1/20 0.43
DAPK3 O43293 1/20 0.43
STK17B O94768 1/20 0.43
DAPK1 P53355 1/20 0.43
STK17A Q9UEE5 1/20 0.43
ULK1 O75385 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13608534 0.90 AURKB (0.79) AURKBSRCGSK3BAURKAAURKC
SCHEMBL12430615 0.89 AURKB (0.76) AURKBSRCGSK3BAURKAAURKC
SCHEMBL12430558 0.88 AURKB (0.72) AURKBSRCGSK3BAURKAAURKC
SCHEMBL2201390 0.86 AURKB (0.54) AURKBSRCGSK3BAURKAAURKC
SCHEMBL12430554 0.85 GSK3B (1.00) AURKBSRCGSK3BAURKAAURKC
SCHEMBL13054580 0.82 AURKB (0.49) AURKBSRCGSK3BAURKAIGF1R
SCHEMBL2200771 0.81 AURKB (0.53) AURKBSRCGSK3BAURKAAURKC
SCHEMBL12430989 0.79 SRC (0.74) AURKBSRCGSK3BAURKAAURKC
SCHEMBL12430576 0.77 AURKA (0.77) AURKBSRCGSK3BAURKAAURKC
SCHEMBL13313947 0.76 AURKB (0.69) AURKBSRCGSK3BAURKAAURKC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7982037-B2 (5-Methyl-2H-pyrazol-3-yl)-(2-phenylsulfanyl-quinazolin-4-yl)-amine; Anticancer agents; antidiabetic agents; Alzheimer's disease; inhibitors of Aurora-2 and GSK-3 VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-07-19 US disclosed
US-7982037-B2 (5-Methyl-2H-pyrazol-3-yl)-(2-phenylsulfanyl-quinazolin-4-yl)-amine; Anticancer agents; antidiabetic agents; Alzheimer's disease; inhibitors of Aurora-2 and GSK-3 VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-07-19 US disclosed
US-20090312543-A1 PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-12-17 US disclosed
US-20090312543-A1 PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-12-17 US disclosed
US-7625913-B2 Pyrazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-12-01 US disclosed
US-7531536-B2 Pyrazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-05-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312543-A1 PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS GSK3B, AURKC, AURKA AURKB 7/4885SRC 298/4885GSK3B 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.